Abstract: Systems, methods, and apparatus for a memory device having test mode state machines configured to perform self-testing. In one approach, a memory array has memory cells. Periphery logic of the memory device receives a command from a host device to initiate self-testing. The periphery logic generates trigger signal(s) in response to receiving the command. Control circuitry (e.g., a controller) has state machine(s) that receives the trigger signal(s) and initiates execution of a command sequence. The command sequence includes various orders of operations such as read, write, or delay. A state machine can be integrated into each of multiple partitions of the memory array.

Abstract: Disclosed are methods, compositions of matter and protocols useful for restoring/enhancing endometrial function by use of gene therapy. In one embodiment genes associated with endometrial preservation and/or regeneration are inserted into the endometrium and/or accessory tissues. Suppression of fibrosis, inflammation and stimulation of regeneration is accomplished by the practice of the current invention.

Abstract: Provided herein are 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)thiophene-2-carboxamide derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Disclosed are novel means of generating cells uniquely suited for treatment of ovarian failure. In one embodiment regenerative cells are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment regenerative cells are cultured with primed plasma extracts. In another embodiment, regenerative cells are cultured under hypoxic conditions together with cytokines prior to administration to an individual. Regenerative cells useful for the current invention including mesenchymal and hematopoietic stem cells, as well as various growth factor producing cells.

Abstract: Disclosed are compositions of matter, protocols, and procedures useful for generation of mesenchymal stem cells capable of withstanding the microenvironment of degenerating ovaries. In one embodiment mesenchymal stem cells are pre-treated under conditions capable of upregulating cytoprotective responses and genes, such as HIF-1 alpha and hemoxygenase. In other embodiments mesenchymal stem cells are temporarily pulsed with hypoxia and/or acidity in order to prime them for the harsh environment of degenerating ovarian tissue. Through this approach increased viability of mesenchymal stem cell subsequent to intra-ovarian administration is achieved.

Abstract: Disclosed are compositions of matter, protocols and procedures useful for preventing/treatment ovarian failure. In one embodiment cytokines promoting anti-inflammatory/regenerative activity are administered systemically, or locally in order to preventing ovarian degeneration/fibrosis. In one embodiment low dose interleukin-2 is administered either alone or with adjuvant cytokines to induce an increase in FoxP3 expressing CD4 cells. In some embodiments in vivo generation of FoxP3 expressing CD4 cells is associated with stimulation of intra-ovarian angiogenesis and prevention of fibrosis.

Abstract: Described are protocols, compositions of matter and therapeutic means useful for treatment of ovarian failure caused by oncology treatments. The utilization of natural killer cells allows for dual activity of tissue regeneration in the ovary, while concurrently inhibiting possibility of oncology relapse. In embodiments NK cells are injected as an adjuvant to stem cell and/or regenerative cell therapy to not only enhance therapeutic effect but also to reduce probability of tumor relapse.

Abstract: Disclosed are means and methods useful in selecting osteoarthritis patients most likely to respond to regenerative medicine therapy. One means of practicing the invention is to determine quantity and quality of inflammatory exosomes generated from the tissue adjacent to the injured cartilage. In another embodiment the invention provides detection of exosomes produced by inflammatory processes local or systemic to the body. In some embodiments therapies are tailored to the extent of inflammatory exosomes.

Abstract: Disclosed are methods, protocols and compositions of matter using for treatment of ovarian failure through administration of cells expressing FoxP3 as a monotherapy or as a facilitator to enhance therapeutic efficacy of cells and/or cytokines. In one embodiment FoxP3 expressing cells are concentrated from allogeneic umbilical cord blood, activated ex vivo with anti-CD3 and anti-CD28 antibodies and administered into the ovary alone or with regenerative cells such as stem cells. In one embodiment stem cells administered are of the CD105 expressing lineage.

Abstract: Disclosed are means of assessing the likelihood of a patient to respond positively to stem cell therapy for cartilage regeneration. In one embodiment enhanced inflammatory cytokines are reduced anti-inflammatory cytokines are assessed in the plasma of a potential patient to assess likelihood of response to therapy. In other embodiments intra-articular or synovial fluid is assessed for levels of cytokines that are detrimental to the success of the stem cell therapy. In other embodiments quality of stem cells in the patient are assessed for cytokine to determine suitability for use in stem cell therapy.

Abstract: Disclosed are methods, protocols and compositions of matter useful for the treatment of menopause associated reduction in bone density or osteoporosis. In one embodiment patients with increasing follicle stimulating hormone are administered regenerative cells into the ovarian follicle. Regenerative cells may be from autologous, allogeneic or xenogeneic sources. In some embodiments regenerative cells are from bone marrow, placental, umbilical cord, cord blood, menstrual blood or peripheral blood origin.

Abstract: Method of treating a respiratory condition in a subject by infusing a composition comprising stem or progenitor cells to a subject having a respiratory condition, wherein the stem or progenitor cells express at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105 and wherein the stem or progenitor cells do not express at least five cell markers selected from the group consisting of NANOG, CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Abstract: Disclosed are means, methods, and compositions of matter useful for treatment of neuroinflammation, autoimmunity, transplant rejection, or graft versus host disease (GVHD) comprising exposing autologous immune cells to allogeneic amniotic fluid derived stem cells. In one embodiment peripheral blood mononuclear cells are cultured in the presence of amniotic fluid stem cells in the presence of interleukin-2 for a period of time sufficient to endow tolerogenic properties. Said tolerogenic properties include ability to suppress adaptive or innate immune responses. In another embodiment the invention provides methods of generating antigen specific immune regulatory cells by culture of lymphocytes together with amniotic fluid stem cells in the presence of antigen to which specific immune regulation is desired.

Abstract: A hydraulic pump to synchronize the operation of a pair of hydraulic actuators wherein each hydraulic actuator comprises a cylinder including a first fluid port and a second fluid port formed in the proximal and distal end portions thereof respectively and having a piston disposed therein coupled to a piston rod at least partially disposed within the corresponding cylinder. The dual hydraulic pump includes a triple gear assembly to alternately feed pressurized hydraulic fluid to the first fluid port of each hydraulic actuator simultaneously or the second fluid port of each hydraulic actuator simultaneously to synchronize the linear movement of each piston and piston rod in a first direction or a second direction.

Abstract: Disclosed are means of augmenting efficacy of stem cell therapy for articular tissues through introduction of a step to reduce oxidative stress inside the joint before administration of stem cells. In one embodiment reduction of oxidative stress and/or inflammation is accomplished by administration of anti-oxidant agents locally in the tissue in which stem cell administration is anticipated to. In one embodiment administration of hydrogen gas is provided as a “preconditioning” step before administration of stem cell therapy. In one embodiment cell therapy is a same day non manipulated procedure involving administration of bone marrow aspirate.

Abstract: Disclosed are therapeutic means of suppressing degeneration of cartilage in conditions such as arthritis or other degenerative pathologies through administration of myeloid derived suppressor cells or exosomes produced by said cells. In one embodiment myeloid derived suppressor cells are generated by intravenous administration of a mobilizing cytokines followed by collection of myeloid derived suppressor cells through an apheresis means, followed by subsequent introduction into the intra-articular space. In other embodiments allogeneic myeloid derived suppressor cells are administered from an allogeneic source such as umbilical cord blood mononuclear cells.

Abstract: Methods of enhancing efficacy of cartilage regenerative therapies through reducing particulate and/or cellular debris residing in the intra-articular space. In one embodiment the invention teaches administration of low-dose protease and/or matrix metalloprotease and/or hyaluronidase prior to administration of stem cells in order to clear tissue of debris capable of suppressing regenerative activity of stem cells. In one embodiment of the invention clinical grade hyaluronidase is administered intra-articular in a patient receiving bone marrow aspirate/mononuclear cell therapy.

Abstract: Described are antigen specific and antigen non-specific means of suppressing development of Type 1 Diabetes in a mammal through administration of exosomes, microvesicles or apoptotic bodies from monocytic lineage cells that have been reprogrammed by contact with mesenchymal stem cells and/or mesenchymal stem cell conditioned media. In one embodiment, the invention provides administration of exosomes that have been generated from monocytic cells that have been loaded with tolerogenic antigens and/or epitopes. In another embodiment the invention provides administration of allogeneic myeloid derived exosomes that are loaded with tolerogenic antigens. In another embodiment the invention provides means of stimulating exosome release in vivo from allogeneic cells that have been administered to the patient in need of treatment.

Abstract: Cell populations and methods of use of mononuclear cells (CMNCs) obtained from dissociated vascular lobules of a perinatal tissue cultured to confluency under hypoxia sufficient to induce translocation of HIF-1 alpha.

Abstract: Disclosed are therapeutic compositions and protocols useful for prevention and/or treatment of radiation induced pathology. In one embodiment, the invention provides the use of regenerative cells derived from subepithelial portion of the umbilical cord for suppression of radiation induced injury including hematopoietic, gastrointestinal, vascular and neurological toxicity. In one embodiment the invention provides the use of derivatives of regenerative cells derived from the subepithelial portion of the umbilical cord for treatment of radiation associated pathology. Said derivatives include conditioned media, conditioned media generated from activated regenerative cells, exosomes, and apoptotic bodies. Treatment and/or prophylaxis of acute and/or chronic radiation syndrome is described in the invention.